High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer

Lilian van Wagensveld*, Tom Van Nyen, Daniela Annibali, Gabe S Sonke, Roy F P M Kruitwagen, Frederic Amant, Hugo M Horlings

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

INTRODUCTION: High-grade serous ovarian cancer (HGSOC) is characterized by high mortality and prevalent recurrences. This study investigates the prognostic value of phosphoglycerate dehydrogenase (PHGDH) in HGSOC which has been linked to metabolic reprogramming and recurrences in other cancers. METHODS: Data from 306 patients with advanced-stage HGSOC treated between 2008 and 2015 were analyzed. PHGDH expression levels were determined using immunohistochemistry and categorized as "low" or "high." RESULTS: PHGDH-high was associated with higher FIGO stage and increased use of neoadjuvant chemotherapy. Patients with PHGDH-high tumors had significantly worse survival than PHDH-low, even after adjusting for confounding factors.
Original languageEnglish
Pages (from-to)e1231-e1234
JournalOncologist
Volume29
Issue number9
Early online date26 Jun 2024
DOIs
Publication statusPublished - 6 Sept 2024

Keywords

  • carcinoma
  • female
  • humans
  • ovarian epithelial/drug therapy
  • ovarian neoplasms/pathology
  • phosphoglycerate dehydrogenase/metabolism

Fingerprint

Dive into the research topics of 'High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer'. Together they form a unique fingerprint.

Cite this